Use of squamous cell carcinoma antigen in the management of cervical cancer
DOI:
https://doi.org/10.5327/JBG-2965-3711-2025135113%20Palabras clave:
cervical cancer, antigens, prognostic factorResumen
Introduction: No tumor marker is recommended in the available guidelines for prognostic evaluation, treatment monitoring, and follow-up of patients with cervical cancer. However, the squamous cell carcinoma antigen (SCC-Ag) may play a role as a prognostic factor in the disease. Objective: To carry out a survey with Brazilian gynecologic oncology specialists on their knowledge and use of SCC-Ag in clinical practice. Methods: This was a transversal epidemiological study based on the application of a questionnaire developed on the Google Forms platform, comprised of three questions about the knowledge and use of SCC-Ag in the clinical routine of gynecologic oncology specialists. Results: The questionnaire was sent to 50 gynecologic oncology specialists, and the response rate was 80%. A total of 62.5% (n=25/40) of respondents reported knowing SCC-Ag. However, when asked about the use of SCC-Ag as a prognostic marker during the management of cervical cancer, 36 (90%) specialists stated that they had never requested it. Informed about the cost of the exam, 27 (67.5%) declared that they would request biomarker analysis in their clinical routine. Conclusion: SCC-Ag is the most widely studied tumor marker as a prognostic factor in cervical cancer, but it is underutilized by Brazilian gynecologic oncology specialists, despite their knowledge of this marker and willingness to request it.
Descargas
Citas
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660
Tempfer CB, Beckmann MW. State-of-the-art treatment and novel agents in local and distant recurrences of cervical cancer. Oncol Res Treat. 2016;39(9):525-33. https://doi.org/10.1159/000448529
Kim JY, Byun SJ, Kim YS, Nam JH. Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer. Gynecol Oncol. 2017;144(1):34-9. https://doi.org/10.1016/j.ygyno.2016.10.032
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977;40(4):1621-8. https://doi.org/10.1002/1097-0142(197710)40:4<1621::aid-cncr2820400435>3.0.co;2-i
Choi KH, Lee SW, Yu M, Jeong S, Lee JW, Lee JH. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. J Gynecol Oncol. 2019;30(1):e1. https://doi.org/10.3802/jgo.2019.30.e1
Kang S, Nam BH, Park JY, Seo SS, Ryu SY, Kim JW, et al. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study. J Clin Oncol. 2012;30(19):2369-74. https://doi.org/10.1200/JCO.2011.37.5923
Kawaguchi R, Furukawa N, Kobayashi H, Asakawa I. Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy. J Gynecol Oncol. 2013;24(4):313-20. https://doi.org/10.3802/jgo.2013.24.4.313
Kubik S, Moszynska-Zielinska M, Fijuth J, Tomalczyk A, Jesionek-Kupnicka D, Ura L, et al. Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse. Prz Menopauzalny. 2019;18(1):23-6. https://doi.org/10.5114/pm.2019.84153
Charakorn C, Thadanipon K, Chaijindaratana S, Rattanasiri S, Numthavaj P, Thakkinstian A. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: a systematic review and meta-analysis. Gynecol Oncol. 2018;150(1):190-200. https://doi.org/10.1016/j.ygyno.2018.03.056
Ryu HK, Baek JS, Kang WD, Kim SM. The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients. Obstet Gynecol Sci. 2015;58(5):368-76. https://doi.org/10.5468/ogs.2015.58.5.368
Jeong BK, Huh SJ, Choi DH, Park W, Bae DS, Kim BG. Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer. Cancer Res Treat. 2013;45(1):48-54. https://doi.org/10.4143/crt.2013.45.1.48
Liu Z, Shi H. Prognostic role of squamous cell carcinoma antigen in cervical cancer: a meta-analysis. Dis Markers. 2019;2019:6710352. https://doi.org/10.1155/2019/6710352
Zhang G, Miao L, Wu H, Zhang Y, Fu C. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a predictive factor for the use of consolidation chemotherapy in cervical cancer patients after postoperative extended-field concurrent chemoradiotherapy. Technol Cancer Res Treat. 2021;20:15330338211044626. https://doi.org/10.1177/15330338211044626
